Mastoid Cavity
Conditions
Brief summary
In recent years, mastoid obliteration (MO) after mastoidectomy has gained popularity. However, the choice for obliteration material has been a point of discussion. Autologous materials have the advantage of being freely available without cost.Synthetic materials on the other hand have unlimited supply, hold volume over time and have no risk of donor site morbidity. Comparative studies between materials are rare and the few available were unable to ascertain superiority. Our hospital has been utilizing the same material for obliteration since 2011: S53P4 bioactive glass (BAG). It since has become our main operating procedure to obliterate the mastoid cavity with BAG granules following both canal wall up (CWU) and canal wall down (CWD) mastoidectomy. This bioactive glass has several important characteristics, such as the retaining of volume over time and antibacterial properties. An important factor when selecting obliteration material is safety. Data on this was reported in several studies, but unfortunately these studies only investigated short-term safety in small and selected cohorts of patients, often without comparison. Additionally, large studies with extensive follow-up are necessary to detect rare complications and long-term pitfalls. Therefore, the aim of this study is to determine the safety of BAG in a cohort that encompasses all cases that underwent CWU+MO and CWD+MO in our institute and compare these results to a non-obliteration cohort. The main outcomes are short- and long-term safety, as indicated by surgical complications in the first year following surgery and revision surgeries during follow-up, respectively. The investigators will compare the obliteration cohort to the non-obliteration cohort, hypothesizing that obliteration results in a comparable or lower rate of complications and revision surgeries
Interventions
DEVICES53P4 Bioactive glass
Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
Sponsors
Diakonessenhuis, Utrecht
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Canal wall up or canal wall down mastoidectomy * Operated between 2010 and 2022 * All indications are included
Exclusion criteria
* Other surgical techniques, such as subtotal petrosectomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of patients with postoperative surgical complications in the first year following surgery | First year following surgery | Complications that occured within the first year following surgery We compare the obliteration cohort to the non-obliterative cohort |
| The number of patients which require revision surgery during follow-up | At 3-, 5- and 8-years postoperatively | Revision surgeries performed during follow-up due to problems with the obliteration |
Countries
Netherlands
Outcome results
None listed